MX363403B - Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. - Google Patents
Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.Info
- Publication number
- MX363403B MX363403B MX2015016389A MX2015016389A MX363403B MX 363403 B MX363403 B MX 363403B MX 2015016389 A MX2015016389 A MX 2015016389A MX 2015016389 A MX2015016389 A MX 2015016389A MX 363403 B MX363403 B MX 363403B
- Authority
- MX
- Mexico
- Prior art keywords
- drug antibody
- tracer
- capture
- immunoassay
- suppressed
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 13
- 229940079593 drug Drugs 0.000 title abstract 13
- 210000002966 serum Anatomy 0.000 title abstract 2
- 238000003018 immunoassay Methods 0.000 title 1
- 239000000700 radioactive tracer Substances 0.000 abstract 5
- 238000002965 ELISA Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13175091 | 2013-07-04 | ||
| PCT/EP2014/063891 WO2015000865A1 (en) | 2013-07-04 | 2014-07-01 | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015016389A MX2015016389A (es) | 2016-04-11 |
| MX363403B true MX363403B (es) | 2019-03-22 |
Family
ID=48703341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016389A MX363403B (es) | 2013-07-04 | 2014-07-01 | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10168326B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3017303B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6563910B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102248581B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105378480B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015032960B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2913687C (cg-RX-API-DMAC7.html) |
| MX (1) | MX363403B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2674996C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015000865A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| SG10201510640QA (en) | 2009-10-26 | 2016-01-28 | Hoffmann La Roche | Method For The Production Of A Glycosylated Immunoglobulin |
| KR102116202B1 (ko) | 2010-11-08 | 2020-05-28 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| EP3667321B1 (en) * | 2014-02-11 | 2022-07-27 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| EP3391050B1 (en) | 2015-12-16 | 2020-09-16 | F. Hoffmann-La Roche AG | Three-step acid dissociation enzyme linked immunosorbent (tadelis) assay |
| EP3592367B1 (en) * | 2017-03-07 | 2025-04-23 | Roche Diagnostics GmbH | Stable formulations for immune-modulatory macrolides |
| WO2019030202A1 (en) * | 2017-08-08 | 2019-02-14 | F. Hoffmann-La Roche Ag | METHOD FOR DETECTION OF ANTI-MEDICATION ANTIBODIES IN A MINI-PORK SAMPLE |
| WO2019105916A1 (en) * | 2017-11-29 | 2019-06-06 | F. Hoffmann-La Roche Ag | Target interference suppressed anti-drug antibody assay |
| MX2021000331A (es) * | 2018-07-10 | 2021-03-25 | Regeneron Pharma | Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada). |
| WO2020229378A1 (en) * | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
| US11913945B2 (en) * | 2020-01-02 | 2024-02-27 | Hoffmann-La Roche Inc. | Method for determining the amount of a therapeutic antibody in the brain |
| CN113495141A (zh) * | 2020-03-20 | 2021-10-12 | 迈克生物股份有限公司 | 2019新型冠状病毒IgM抗体检测试剂盒 |
| KR20230009502A (ko) * | 2020-05-18 | 2023-01-17 | 바이오션, 인코포레이티드 | Il6r에 결합하는 항체 및 이의 용도 |
| KR102626197B1 (ko) * | 2020-11-19 | 2024-01-18 | 바디텍메드(주) | 항 약물 항체의 수준을 정확하게 정량화하는 방법 |
| JP7062803B1 (ja) | 2021-03-31 | 2022-05-06 | 積水メディカル株式会社 | 抗薬物抗体測定方法 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| WO2024165456A1 (en) * | 2023-02-07 | 2024-08-15 | F. Hoffmann-La Roche Ag | Method for the detection of anti-aav particle antibodies |
| WO2024220763A1 (en) * | 2023-04-20 | 2024-10-24 | Xentria, Inc. | Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody |
| CN120761634B (zh) * | 2025-09-02 | 2025-12-05 | 宁波熙宁检测技术有限公司 | 一种针对多特异性单克隆抗体药物的ada检测方法 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| JPH066054B2 (ja) | 1987-10-15 | 1994-01-26 | 帝人株式会社 | 動物細胞の培養方法 |
| US6428979B1 (en) | 1988-01-22 | 2002-08-06 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| ZA898290B (en) | 1988-11-03 | 1991-06-26 | Igen Inc | Electrochemiluminescent assays |
| US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| KR0132666B1 (en) | 1989-03-14 | 1998-04-14 | Hitachi Kk | Method for controlling cultivation conditions for animal cells |
| DE122009000023I2 (de) | 1989-07-20 | 2010-12-16 | Kishimoto | Antikörper gegen menschlichen Interleukin-6-Rezeptor |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| ATE181575T1 (de) | 1991-04-25 | 1999-07-15 | Chugai Pharmaceutical Co Ltd | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
| US5821121A (en) | 1991-06-24 | 1998-10-13 | Pacific Biomedical Research, Inc. | Hormone-secreting cells maintained in long-term culture |
| JPH08508875A (ja) | 1992-05-01 | 1996-09-24 | 帝人株式会社 | 蛋白分泌細胞の流加回分培養法 |
| EP0567738A3 (en) | 1992-05-01 | 1995-09-06 | American Cyanamid Co | Controlling perfusion rates in continuous bioreactor culture of animal cells |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| JPH07258252A (ja) | 1994-03-16 | 1995-10-09 | Meiji Seika Kaisha Ltd | チアゾール化合物およびその塩 |
| US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| JP3630453B2 (ja) | 1994-09-30 | 2005-03-16 | 中外製薬株式会社 | Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤 |
| CN100350973C (zh) | 1994-10-21 | 2007-11-28 | 岸本忠三 | 用于治疗il－6产生所致疾病的药物组合物 |
| US6086874A (en) | 1994-12-29 | 2000-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent effect enhancer containing IL-6 antagonist |
| WO1996025174A1 (en) | 1995-02-13 | 1996-08-22 | Chugai Seiyaku Kabushiki Kaisha | Muscle protein decomposition inhibitor containing il-6 receptor antibody |
| US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| CA2238080C (en) | 1995-10-23 | 2012-03-13 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
| US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
| EP0923941B1 (en) | 1996-06-27 | 2006-05-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| WO1998041611A1 (en) | 1997-03-20 | 1998-09-24 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
| WO1998042377A1 (fr) | 1997-03-21 | 1998-10-01 | Chugai Seiyaku Kabushiki Kaisha | Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6 |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| ATE383875T1 (de) | 1998-03-17 | 2008-02-15 | Chugai Pharmaceutical Co Ltd | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper |
| US6537782B1 (en) | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
| ATE350060T1 (de) | 1998-08-24 | 2007-01-15 | Chugai Pharmaceutical Co Ltd | Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten |
| US6284453B1 (en) | 1999-09-29 | 2001-09-04 | Steven Anthony Siano | Method for controlling fermentation growth and metabolism |
| AU2001271021A1 (en) | 2000-07-05 | 2002-01-14 | Japan As Represented By Secretary Of Osaka University | Process for producing glycoprotein |
| WO2002013859A1 (en) | 2000-08-10 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Method of inhibiting antibody-containing solution from coagulating or becoming turbid |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| EP1324776B2 (en) | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US7358067B2 (en) | 2000-10-20 | 2008-04-15 | Bioneer A/S | Fermentation method for production of heterologous gene products in lactic acid bacteria |
| EP2351838A1 (en) | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Crosslinking agonistic antibodies |
| AU2002210952B2 (en) | 2000-10-25 | 2007-01-11 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist |
| AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
| WO2002036164A1 (en) | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| EP2336149A1 (en) | 2001-03-09 | 2011-06-22 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
| AU2002256005A1 (en) | 2001-03-27 | 2002-10-08 | Smithkline Beecham Corporation | Control of glycoforms in igg |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| EP1404813A4 (en) | 2001-06-13 | 2004-11-24 | Genentech Inc | METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS |
| EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| CA2480059C (en) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
| JP3822137B2 (ja) | 2002-05-20 | 2006-09-13 | 中外製薬株式会社 | 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法 |
| EP1561756B1 (en) | 2002-09-11 | 2015-12-23 | Chugai Seiyaku Kabushiki Kaisha | Method of purifying protein |
| US7550262B2 (en) | 2002-11-05 | 2009-06-23 | Mount Sinai School Of Medicine Of New York University | PTPN11 (SHP-2) mutations and cancer |
| DE10255508A1 (de) | 2002-11-27 | 2004-06-17 | Forschungszentrum Jülich GmbH | Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen |
| JP4555924B2 (ja) | 2003-02-24 | 2010-10-06 | 中外製薬株式会社 | インターロイキン−６アンタゴニストを含有する脊髄損傷治療剤 |
| US20060239927A1 (en) | 2003-03-31 | 2006-10-26 | Kyowa Hakko Kogyo Co., | Drug for airway administration |
| JP4473257B2 (ja) | 2003-04-02 | 2010-06-02 | エフ．ホフマン−ラ ロシュ アーゲー | インスリン様成長因子ｉ受容体に対する抗体及びその使用 |
| JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| DK1623019T4 (en) | 2003-05-15 | 2017-03-27 | Wyeth Llc | LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| CA2542691C (en) | 2003-10-17 | 2013-09-24 | Chugai Seiyaku Kabushiki Kaisha | Il-6 antagonist for use as mesothelioma therapeutic agent |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| JPWO2005090405A1 (ja) | 2004-03-24 | 2008-04-17 | 中外製薬株式会社 | インターロイキン−６受容体に対するヒト型化抗体のサブタイプ |
| AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| KR20130101161A (ko) | 2005-01-05 | 2013-09-12 | 추가이 세이야쿠 가부시키가이샤 | 세포의 배양 방법 및 그 이용 |
| CN101330929B (zh) | 2005-10-14 | 2014-03-05 | 学校法人福冈大学 | 胰岛移植中的移植胰岛障碍抑制剂 |
| JP5191235B2 (ja) | 2005-10-21 | 2013-05-08 | 中外製薬株式会社 | 心疾患治療剤 |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| US20090269335A1 (en) | 2005-11-25 | 2009-10-29 | Keio University | Therapeutic agent for prostate cancer |
| US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| CN104189907A (zh) | 2006-01-27 | 2014-12-10 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
| KR101047207B1 (ko) | 2006-03-09 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | 항-약물 항체 분석 |
| US9260516B2 (en) | 2006-04-07 | 2016-02-16 | Osaka University | Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor |
| WO2008016134A1 (fr) | 2006-08-04 | 2008-02-07 | Norihiro Nishimoto | PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde |
| TWI434855B (zh) | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
| JP2010095445A (ja) | 2006-12-27 | 2010-04-30 | Tokyo Medical & Dental Univ | Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤 |
| KR101508019B1 (ko) | 2007-01-23 | 2015-04-06 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 만성 거부반응 억제제 |
| US20100129355A1 (en) | 2007-07-26 | 2010-05-27 | Osaka University | Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient |
| MX2010003329A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6. |
| KR101601986B1 (ko) | 2007-10-02 | 2016-03-17 | 추가이 세이야쿠 가부시키가이샤 | 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제 |
| CA2701338C (en) | 2007-10-15 | 2018-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for production of antibody |
| ES2532483T3 (es) | 2007-12-15 | 2015-03-27 | F. Hoffmann-La Roche Ag | Ensayo de distinción |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| DE102008005523A1 (de) | 2008-01-23 | 2009-07-30 | Robert Bosch Gmbh | Kraftstoffinjektor |
| JP2011512875A (ja) | 2008-03-11 | 2011-04-28 | ジェネンテック， インコーポレイテッド | 増強されたａｄｃｃ機能を有する抗体 |
| DE102008013899A1 (de) | 2008-03-12 | 2009-09-17 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium |
| CA2728243C (en) | 2008-06-05 | 2020-03-10 | National Cancer Center | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US20120183539A1 (en) | 2009-07-31 | 2012-07-19 | Shin Maeda | Cancer Metastasis Inhibitor |
| WO2011019622A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Cell culture methods to make antibodies with enhanced adcc function |
| SG10201510640QA (en) | 2009-10-26 | 2016-01-28 | Hoffmann La Roche | Method For The Production Of A Glycosylated Immunoglobulin |
| WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| SI2578231T1 (sl) | 2010-05-28 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Okrepljen protitumorski T celični odzivnik |
| US20130149302A1 (en) | 2010-05-28 | 2013-06-13 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for pancreatic cancer |
| CN103119176A (zh) | 2010-06-07 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用于预测对白介素-6受体抑制性单克隆抗体药物治疗的响应的基因表达标记 |
| KR102116202B1 (ko) | 2010-11-08 | 2020-05-28 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| JP6363017B2 (ja) | 2011-09-01 | 2018-07-25 | 中外製薬株式会社 | 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法 |
-
2014
- 2014-07-01 EP EP14734471.7A patent/EP3017303B1/en active Active
- 2014-07-01 BR BR112015032960-8A patent/BR112015032960B1/pt active IP Right Grant
- 2014-07-01 CN CN201480037364.5A patent/CN105378480B/zh active Active
- 2014-07-01 CA CA2913687A patent/CA2913687C/en active Active
- 2014-07-01 KR KR1020157037229A patent/KR102248581B1/ko active Active
- 2014-07-01 MX MX2015016389A patent/MX363403B/es unknown
- 2014-07-01 RU RU2016101730A patent/RU2674996C2/ru active
- 2014-07-01 JP JP2016522572A patent/JP6563910B2/ja active Active
- 2014-07-01 WO PCT/EP2014/063891 patent/WO2015000865A1/en not_active Ceased
-
2016
- 2016-03-23 US US15/078,140 patent/US10168326B2/en active Active
-
2018
- 2018-11-21 US US16/197,902 patent/US10761091B2/en active Active
-
2019
- 2019-07-25 JP JP2019137030A patent/JP6761085B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6761085B2 (ja) | 2020-09-23 |
| RU2016101730A (ru) | 2017-08-09 |
| JP6563910B2 (ja) | 2019-08-21 |
| EP3017303A1 (en) | 2016-05-11 |
| MX2015016389A (es) | 2016-04-11 |
| US20190094216A1 (en) | 2019-03-28 |
| BR112015032960A8 (pt) | 2019-12-31 |
| KR20160029034A (ko) | 2016-03-14 |
| JP2016530495A (ja) | 2016-09-29 |
| JP2019207246A (ja) | 2019-12-05 |
| WO2015000865A1 (en) | 2015-01-08 |
| HK1217759A1 (zh) | 2017-01-20 |
| CN105378480B (zh) | 2018-06-12 |
| CA2913687C (en) | 2022-12-13 |
| CN105378480A (zh) | 2016-03-02 |
| US20160313322A1 (en) | 2016-10-27 |
| BR112015032960B1 (pt) | 2021-01-05 |
| US10168326B2 (en) | 2019-01-01 |
| RU2674996C2 (ru) | 2018-12-14 |
| KR102248581B1 (ko) | 2021-05-06 |
| US10761091B2 (en) | 2020-09-01 |
| EP3017303B1 (en) | 2018-01-03 |
| CA2913687A1 (en) | 2015-01-08 |
| RU2016101730A3 (cg-RX-API-DMAC7.html) | 2018-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX363403B (es) | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. | |
| NO20076662L (no) | Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff | |
| MX2015012823A (es) | Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo. | |
| EA202190237A1 (ru) | Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada) | |
| EP3933406A3 (en) | Antibodies to risperidone and use thereof | |
| BR112015023355A2 (pt) | antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada | |
| MX2014010068A (es) | Metodos y sistemas para amplificacion de señal de bioensayos. | |
| MX2009012048A (es) | Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato. | |
| EA201370030A1 (ru) | Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням | |
| BR112018017336A2 (pt) | método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão | |
| EP4196770A4 (en) | TR-FRET-BASED ASSAY FOR THE DETECTION OF ANTIBODIES IN SEROLOGICAL SAMPLES | |
| WO2021222597A3 (en) | Rapid diagnostic immunoassay for presence of antibodies | |
| NZ603340A (en) | Yeast cell wall components and detection thereof | |
| EP4257976A3 (en) | Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis | |
| MX2017005156A (es) | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. | |
| EA201400356A1 (ru) | Иммуноанализ для обнаружения антибиотиков | |
| EA200700345A1 (ru) | Обогащённое антитело для выявления микобактериальной инфекции, способы применения и диагностические тесты, применяющие такое антитело | |
| RU2014140135A (ru) | Мультиплексный иммунохроматографический способ определения циркулирующих иммунокомплексов | |
| FR2968767B1 (fr) | Procede et coffret pour le diagnostic in vitro du cancer de la prostate | |
| MX2015013364A (es) | Deteccion especifica de anticuerpos de rata en suero de raton. | |
| MY151190A (en) | Method of detecting pork in processed food and detection kit therefor | |
| RU2012127077A (ru) | Методика проведения иммунохроматографического анализа для серодиагностики | |
| JP2015517658A5 (cg-RX-API-DMAC7.html) | ||
| MY194325A (en) | Test object detection method, and immunoassay instrument and monoclonal antibody for same | |
| MX2020011249A (es) | Dispositivo microfluidico multiplexado de alto rendimiento para la deteccion confiable de covid-19 mediante ensayos serologicos. |